Alto Neuroscience, Inc. cash flow to debt ratio of -1.17K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Alto Neuroscience, Inc.'s free cash flow has decreased 4.63% from $-49.50M last year to $-51.79M, signaling decreasing performance

Alto Neuroscience, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Alto Neuroscience, Inc.'s debt has decreased relative to shareholder equity from 0.11 last year to 0.02 today, signaling strengthened financials

Alto Neuroscience, Inc. has a net cash position, so leverage is healthy.

Alto Neuroscience, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Alto Neuroscience, Inc. has insufficient data to evaluate this check.

Alto Neuroscience, Inc.'s short-term assets of $177.72M exceed its short-term liabilities of $11.32M

Alto Neuroscience, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Alto Neuroscience, Inc.'s return on equity of -47.22%, is lower than 15.00%, indicating bad performance

Alto Neuroscience, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Alto Neuroscience, Inc. has insufficient public price history to evaluate earnings stability.

Alto Neuroscience, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Alto Neuroscience, Inc. has negative free cash flow, indicating cash burn

Alto Neuroscience, Inc.'s yearly earnings has decreased 2.94% since last year from $-61.43M to $-63.24M, signaling decreasing performance

Alto Neuroscience, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 20.70% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Alto Neuroscience, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Alto Neuroscience, Inc. has insufficient public price history to evaluate revenue consistency.

Alto Neuroscience, Inc. has insufficient public price history to evaluate ROE consistency.

Alto Neuroscience, Inc. has insufficient data to evaluate this check.

Alto Neuroscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Alto Neuroscience, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Alto Neuroscience, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Alto Neuroscience, Inc. has insufficient data to evaluate this check.

Alto Neuroscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Alto Neuroscience, Inc. has a price-to-book ratio of 3.82x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Alto Neuroscience, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue